Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
Mes dernières consult.
Most popular
End-of-day quote. End-of-day quote  - 10/23
16.255 EUR   -0.73%
07:32a ABLYNX : 23/10/2017 ablynx announces warrant exercise
07:01a ABLYNX : Announces warrant exercise
07:01a ABLYNX : Announces warrant exercise
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Ablynx : ANNOUNCES WARRANT EXERCISE

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/14/2017 | 07:01am CEST

REGULATED INFORMATION

GHENT, Belgium, 14 September 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 249,563 common shares have been issued by the Company in exchange for €878,950 as the result of the exercise of warrants.

As a result of this transaction, Ablynx now has 61,419,295 shares outstanding.

The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights currently is 2,622,414 which equals the total number of voting rights that may result from the exercise of these warrants. Currently 1,000 convertible bonds are outstanding entitling the holders thereof to 7,733,952 shares of the Company in the aggregate, upon conversion of such convertible bonds.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t:   +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e:  [email protected]

Lies Vanneste
Director Investor Relations
t:   +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e:  [email protected]

Follow us on Twitter @AblynxABLX

Ablynx media relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t:  +44 (0)20 3709 5700
e:  [email protected]





This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABLYNX
07:32a ABLYNX : 23/10/2017 ablynx announces warrant exercise
07:01a ABLYNX : Announces warrant exercise
07:01a ABLYNX : Announces warrant exercise
10/17 ABLYNX : 17/10/2017 ablynx announces launch of proposed global offering
10/17 ABLYNX : Announces launch of proposed global offering
10/16 ABLYNX : 16/10/2017 ablynx establishes subsidiary in the usa and appoints a gene..
10/16 ABLYNX : 16/10/2017 publication in accordance with article 14 of the belgian law..
10/16 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
10/16 ABLYNX : Establishes subsidiary in the usa and appoints a general manager
10/16 ABLYNX : Establishes subsidiary in the usa and appoints a general manager
More news
News from SeekingAlpha
10/18 YOUR DAILY PHARMA SCOOP : AZN's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?
10/17 Ablynx prices $175M U.S. IPO at $20.95
10/04 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 4, 2017
10/03 YOUR DAILY PHARMA SCOOP : Pfizer A Buy, Our Ablynx Pick Successful, VBLT, DVAX, ..
10/02 Ablynx's caplacizumab successful in late-stage study in rare blood disorder; ..
Financials (€)
Sales 2017 59,0 M
EBIT 2017 -55,7 M
Net income 2017 -75,2 M
Finance 2017 8,18 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 16,9x
EV / Sales 2018 18,2x
Capitalization 1 006 M
Chart ABLYNX
Duration : Period :
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Technical analysis trends ABLYNX
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 18,4 €
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Edwin Moses Chief Executive Officer & Executive Director
Peter John Fellner Chairman
Wim Ottevaere Chief Financial Officer
Antonin Rollet de Fougerolles Chief Scientific Officer
Robert K. Zeldin Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX51.41%1 185
INCYTE CORPORATION13.88%24 054
QUINTILES IMS HOLDINGS INC35.48%22 162
LONZA GROUP57.01%19 392
CELLTRION, INC.--.--%19 297
ALNYLAM PHARMACEUTICALS, INC.206.36%10 522